News

DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)

Exactis is pleased to be working with Dr. Jonathan Spicer on a phase I interventional pilot open-label trial, using rhDNase1 as a treatment for COVID-19...
exactis

Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC within the Exactis Network

The Exactis-01 trial, a PMT sub-study “Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA)...
exactis

A  Phase I/II Basket Trial of the Combination of Veliparib and Navitoclax in  Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer

The Exactis-03 trial “A  Phase I/II Basket Trial of the Combination of Veliparib and Navitoclax in  Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer” led by Dr. Helen MacKay...
exactis

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation

Sermonix Pharmaceuticals’ study “Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation.” The clinical trial is ongoing in the...
exactis

Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway

Exactis is pleased to be working with Dr. Sébastien Perreault from CHU Ste-Justine on the TRAM-01 study, “ Phase 2 study of Trametinib for patients...
exactis

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

Our new manuscript “Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition” is now available in Clinical Proteomics. Our...
exactis

COVID-19 Response

Dear Exactis Network,  With the current and ever-evolving situation with COVID-19, we wanted to provide you with an update on our response to date and our commitment moving...
exactis

Exactis Innovation to drive network-based precision oncology research with $1M grant

Exactis Innovation is pleased to award $1M CDN to catalyze clinical research on innovative precision oncology therapeutics in Canada. This grant will support a multi-centre...
exactis

Exactis Helps Found an Innovative Precision Oncology Collaboration with Major Partners Harnessing Longitudinal Patient Registry and Artificial Intelligence for Triple-Negative Breast Cancer

The TRICIA Study, a research project pairing molecular data with artificial intelligence, was awarded funding of $1.6 million this week by the Biopharmaceutical Research Consortium...
exactis
1 2